Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 87 entries
Sorted by: Best Match Show Resources per page
What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?.

Patient preference and adherence

Lloyd AJ, Nafees B, Ziani E, Nicolas L, Fordham BA, Soubeyrand B, Bornhöft C.
PMID: 26604704
Patient Prefer Adherence. 2015 Oct 27;9:1517-24. doi: 10.2147/PPA.S87229. eCollection 2015.

Diphtheria, tetanus and acellular pertussis (DTaP) based combined vaccines have led to significant reduction in incidence of several serious pediatric infectious diseases. A new, fully liquid combined hexavalent vaccine has been introduced and has been shown to reduce administration...

Cite
Lloyd AJ, Nafees B, Ziani E, et al. What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?. Patient Prefer Adherence. 2015;9:1517-24doi: 10.2147/PPA.S87229.
Lloyd, A. J., Nafees, B., Ziani, E., Nicolas, L., Fordham, B. A., Soubeyrand, B., & Bornhöft, C. (2015). What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?. Patient preference and adherence, 91517-24. https://doi.org/10.2147/PPA.S87229
Lloyd, Andrew J, et al. "What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?." Patient preference and adherence vol. 9 (2015): 1517-24. doi: https://doi.org/10.2147/PPA.S87229
Lloyd AJ, Nafees B, Ziani E, Nicolas L, Fordham BA, Soubeyrand B, Bornhöft C. What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?. Patient Prefer Adherence. 2015 Oct 27;9:1517-24. doi: 10.2147/PPA.S87229. eCollection 2015. PMID: 26604704; PMCID: PMC4630204.
Copy Download .nbib Format: NLM
Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination.

Cancers

Latour S, Mahouche I, Cherrier F, Azzi-Martin L, Velasco V, Soubeyran P, Merlio JP, Poglio S, Bresson-Bepoldin L.
PMID: 30373149
Cancers (Basel). 2018 Oct 26;10(11). doi: 10.3390/cancers10110402.

Ca

Cite
Latour S, Mahouche I, Cherrier F, et al. Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination. Cancers (Basel). 2018;10(11)doi: 10.3390/cancers10110402.
Latour, S., Mahouche, I., Cherrier, F., Azzi-Martin, L., Velasco, V., Soubeyran, P., Merlio, J. P., Poglio, S., & Bresson-Bepoldin, L. (2018). Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination. Cancers, 10(11), . https://doi.org/10.3390/cancers10110402
Latour, Simon, et al. "Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination." Cancers vol. 10,11 (2018). doi: https://doi.org/10.3390/cancers10110402
Latour S, Mahouche I, Cherrier F, Azzi-Martin L, Velasco V, Soubeyran P, Merlio JP, Poglio S, Bresson-Bepoldin L. Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination. Cancers (Basel). 2018 Oct 26;10(11). doi: 10.3390/cancers10110402. PMID: 30373149; PMCID: PMC6267368.
Copy Download .nbib Format: NLM
Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells.

Oncotarget

Boudouresque F, Siret C, Dobric A, Silvy F, Soubeyran P, Iovanna J, Lombardo D, Berthois Y.
PMID: 30542509
Oncotarget. 2018 Nov 13;9(89):35941-35961. doi: 10.18632/oncotarget.26310. eCollection 2018 Nov 13.

The microRNA-200 (miR-200) family is frequently down-regulated in tumors, including pancreatic adenocarcinomas (PDACs). In this study we have examined the mechanisms involved in the loss of miR-200s in tumoral pancreatic cells. Whereas miR-200 gene promoters appear methylated in mature...

Cite
Boudouresque F, Siret C, Dobric A, et al. Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells. Oncotarget. 2018;9(89):35941-35961doi: 10.18632/oncotarget.26310.
Boudouresque, F., Siret, C., Dobric, A., Silvy, F., Soubeyran, P., Iovanna, J., Lombardo, D., & Berthois, Y. (2018). Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells. Oncotarget, 9(89), 35941-35961. https://doi.org/10.18632/oncotarget.26310
Boudouresque, Françoise, et al. "Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells." Oncotarget vol. 9,89 (2018): 35941-35961. doi: https://doi.org/10.18632/oncotarget.26310
Boudouresque F, Siret C, Dobric A, Silvy F, Soubeyran P, Iovanna J, Lombardo D, Berthois Y. Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells. Oncotarget. 2018 Nov 13;9(89):35941-35961. doi: 10.18632/oncotarget.26310. eCollection 2018 Nov 13. PMID: 30542509; PMCID: PMC6267598.
Copy Download .nbib Format: NLM
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.

European journal of cancer (Oxford, England : 1990)

Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, Bellera C, Adenis A, Korakis I, Poureau PG, Bourcier K, Toulmonde M, Kind M, Rey C, Auzanneau C, Bessede A, Soubeyran I, Italiano A.
PMID: 34998048
Eur J Cancer. 2022 Jan 05;162:161-169. doi: 10.1016/j.ejca.2021.11.012. Epub 2022 Jan 05.

BACKGROUND: Regorafenib has shown substantial clinical activity in patients with advanced biliary tract cancers (BTCs). Preclinical data suggested that this drug modulates antitumour immunity and is synergistic with immune checkpoint inhibition.PATIENTS AND METHODS: This is a single-arm, multicentric phase...

Cite
Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022;162:161-169doi: 10.1016/j.ejca.2021.11.012.
Cousin, S., Cantarel, C., Guegan, J. P., Mazard, T., Gomez-Roca, C., Metges, J. P., Bellera, C., Adenis, A., Korakis, I., Poureau, P. G., Bourcier, K., Toulmonde, M., Kind, M., Rey, C., Auzanneau, C., Bessede, A., Soubeyran, I., & Italiano, A. (2022). Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. European journal of cancer (Oxford, England : 1990), 162161-169. https://doi.org/10.1016/j.ejca.2021.11.012
Cousin, Sophie, et al. "Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 161-169. doi: https://doi.org/10.1016/j.ejca.2021.11.012
Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, Bellera C, Adenis A, Korakis I, Poureau PG, Bourcier K, Toulmonde M, Kind M, Rey C, Auzanneau C, Bessede A, Soubeyran I, Italiano A. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022 Jan 05;162:161-169. doi: 10.1016/j.ejca.2021.11.012. Epub 2022 Jan 05. PMID: 34998048.
Copy Download .nbib Format: NLM
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.

Journal of the National Cancer Institute

Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I.
PMID: 33372675
J Natl Cancer Inst. 2021 Jul 01;113(7):917-923. doi: 10.1093/jnci/djaa193.

BACKGROUND: PAOLA1 is a phase III study assessing olaparib maintenance therapy in advanced high-grade ovarian carcinoma patients responding to first-line platinum-taxane-based chemotherapy plus bevacizumab as standard of care. Randomization was stratified by treatment outcome and tumor BRCA1/2 status (tBRCA)...

Cite
Callens C, Vaur D, Soubeyran I, et al. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. J Natl Cancer Inst. 2021;113(7):917-923doi: 10.1093/jnci/djaa193.
Callens, C., Vaur, D., Soubeyran, I., Rouleau, E., Just, P. A., Guillerm, E., Golmard, L., Goardon, N., Sevenet, N., Cabaret, O., Harter, P., Gonzalez-Martin, A., Fujiwara, K., Cecere, S. C., Colombo, N., Marth, C., Vergote, I., Maenpaa, J., Pujade-Lauraine, E., & Ray-Coquard, I. (2021). Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. Journal of the National Cancer Institute, 113(7), 917-923. https://doi.org/10.1093/jnci/djaa193
Callens, Céline, et al. "Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial." Journal of the National Cancer Institute vol. 113,7 (2021): 917-923. doi: https://doi.org/10.1093/jnci/djaa193
Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. J Natl Cancer Inst. 2021 Jul 01;113(7):917-923. doi: 10.1093/jnci/djaa193. PMID: 33372675; PMCID: PMC8246800.
Copy Download .nbib Format: NLM
Superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases.

Histopathology

Perret R, Michal M, Carr RA, Velasco V, Švajdler M, Karanian M, Meurgey A, Paindavoine S, Soubeyran I, Coindre JM, Boidot R, Charon-Barra C, Geneste D, Weingertner N, Pissaloux D, Tirode F, Baud J, Le Loarer F.
PMID: 34121219
Histopathology. 2021 Nov;79(5):810-825. doi: 10.1111/his.14429. Epub 2021 Sep 05.

AIMS: Superficial CD34-positive fibroblastic tumor (SCD34FT) and PRDM10-rearranged soft tissue tumor (PRDM10-STT) are rare mesenchymal tumors. These lesions have clinicopathological similarities, but their relationship remains controversial. This study aimed to characterise a series of cases of SCD34FT and PRDM10-STT.METHODS...

Cite
Perret R, Michal M, Carr RA, et al. Superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases. Histopathology. 2021;79(5):810-825doi: 10.1111/his.14429.
Perret, R., Michal, M., Carr, R. A., Velasco, V., Švajdler, M., Karanian, M., Meurgey, A., Paindavoine, S., Soubeyran, I., Coindre, J. M., Boidot, R., Charon-Barra, C., Geneste, D., Weingertner, N., Pissaloux, D., Tirode, F., Baud, J., & Le Loarer, F. (2021). Superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases. Histopathology, 79(5), 810-825. https://doi.org/10.1111/his.14429
Perret, Raul, et al. "Superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases." Histopathology vol. 79,5 (2021): 810-825. doi: https://doi.org/10.1111/his.14429
Perret R, Michal M, Carr RA, Velasco V, Švajdler M, Karanian M, Meurgey A, Paindavoine S, Soubeyran I, Coindre JM, Boidot R, Charon-Barra C, Geneste D, Weingertner N, Pissaloux D, Tirode F, Baud J, Le Loarer F. Superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases. Histopathology. 2021 Nov;79(5):810-825. doi: 10.1111/his.14429. Epub 2021 Sep 05. PMID: 34121219.
Copy Download .nbib Format: NLM
Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts.

Cancers

Oubaya N, Soubeyran P, Reinald N, Fonck M, Allain M, Zebachi S, Heitz D, Laurent M, Delattre C, Caillet P, Dauba J, Bastuji-Garin S, Albrand G, Bringuier M, Rainfray M, Brain E, Grellety T, Paillaud E, Mathoulin-Pélissier S, Bellera C, Canouï-Poitrine F.
PMID: 34944774
Cancers (Basel). 2021 Dec 07;13(24). doi: 10.3390/cancers13246154.

BACKGROUND: The prognostic assessment of older cancer patients is complicated by their heterogeneity. We aimed to assess the prognostic value of routine inflammatory biomarkers.METHODS: A pooled analysis of prospective multicenter cohorts of cancer patients aged ≥70 was performed. We...

Cite
Oubaya N, Soubeyran P, Reinald N, et al. Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246154.
Oubaya, N., Soubeyran, P., Reinald, N., Fonck, M., Allain, M., Zebachi, S., Heitz, D., Laurent, M., Delattre, C., Caillet, P., Dauba, J., Bastuji-Garin, S., Albrand, G., Bringuier, M., Rainfray, M., Brain, E., Grellety, T., Paillaud, E., Mathoulin-Pélissier, S., Bellera, C., & Canouï-Poitrine, F. (2021). Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. Cancers, 13(24), . https://doi.org/10.3390/cancers13246154
Oubaya, Nadia, et al. "Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246154
Oubaya N, Soubeyran P, Reinald N, Fonck M, Allain M, Zebachi S, Heitz D, Laurent M, Delattre C, Caillet P, Dauba J, Bastuji-Garin S, Albrand G, Bringuier M, Rainfray M, Brain E, Grellety T, Paillaud E, Mathoulin-Pélissier S, Bellera C, Canouï-Poitrine F. Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. Cancers (Basel). 2021 Dec 07;13(24). doi: 10.3390/cancers13246154. PMID: 34944774.
Copy Download .nbib Format: NLM
Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts.

Cancers

Oubaya N, Soubeyran P, Reinald N, Fonck M, Allain M, Zebachi S, Heitz D, Laurent M, Delattre C, Caillet P, Dauba J, Bastuji-Garin S, Albrand G, Bringuier M, Rainfray M, Brain E, Grellety T, Paillaud E, Mathoulin-Pélissier S, Bellera C, Canouï-Poitrine F.
PMID: 34944774
Cancers (Basel). 2021 Dec 07;13(24). doi: 10.3390/cancers13246154.

BACKGROUND: The prognostic assessment of older cancer patients is complicated by their heterogeneity. We aimed to assess the prognostic value of routine inflammatory biomarkers.METHODS: A pooled analysis of prospective multicenter cohorts of cancer patients aged ≥70 was performed. We...

Cite
Oubaya N, Soubeyran P, Reinald N, et al. Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246154.
Oubaya, N., Soubeyran, P., Reinald, N., Fonck, M., Allain, M., Zebachi, S., Heitz, D., Laurent, M., Delattre, C., Caillet, P., Dauba, J., Bastuji-Garin, S., Albrand, G., Bringuier, M., Rainfray, M., Brain, E., Grellety, T., Paillaud, E., Mathoulin-Pélissier, S., Bellera, C., & Canouï-Poitrine, F. (2021). Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. Cancers, 13(24), . https://doi.org/10.3390/cancers13246154
Oubaya, Nadia, et al. "Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246154
Oubaya N, Soubeyran P, Reinald N, Fonck M, Allain M, Zebachi S, Heitz D, Laurent M, Delattre C, Caillet P, Dauba J, Bastuji-Garin S, Albrand G, Bringuier M, Rainfray M, Brain E, Grellety T, Paillaud E, Mathoulin-Pélissier S, Bellera C, Canouï-Poitrine F. Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. Cancers (Basel). 2021 Dec 07;13(24). doi: 10.3390/cancers13246154. PMID: 34944774; PMCID: PMC8699299.
Copy Download .nbib Format: NLM
Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France.

Frontiers in medicine

Roques L, Klein EK, Papaïx J, Sar A, Soubeyrand S.
PMID: 32582739
Front Med (Lausanne). 2020 Jun 05;7:274. doi: 10.3389/fmed.2020.00274. eCollection 2020.

The COVID-19 epidemic was reported in the Hubei province in China in December 2019 and then spread around the world reaching the pandemic stage at the beginning of March 2020. Since then, several countries went into lockdown. Using a...

Cite
Roques L, Klein EK, Papaïx J, et al. Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France. Front Med (Lausanne). 2020;7:274doi: 10.3389/fmed.2020.00274.
Roques, L., Klein, E. K., Papaïx, J., Sar, A., & Soubeyrand, S. (2020). Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France. Frontiers in medicine, 7274. https://doi.org/10.3389/fmed.2020.00274
Roques, Lionel, et al. "Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France." Frontiers in medicine vol. 7 (2020): 274. doi: https://doi.org/10.3389/fmed.2020.00274
Roques L, Klein EK, Papaïx J, Sar A, Soubeyrand S. Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France. Front Med (Lausanne). 2020 Jun 05;7:274. doi: 10.3389/fmed.2020.00274. eCollection 2020. PMID: 32582739; PMCID: PMC7290065.
Copy Download .nbib Format: NLM
Kaempferol as a precursor for ubiquinone (coenzyme Q) biosynthesis: An atypical node between specialized metabolism and primary metabolism.

Current opinion in plant biology

Berger A, Latimer S, Stutts LR, Soubeyrand E, Block AK, Basset GJ.
PMID: 35026487
Curr Opin Plant Biol. 2022 Jan 10;66:102165. doi: 10.1016/j.pbi.2021.102165. Epub 2022 Jan 10.

Ubiquinone (coenzyme Q) is a vital respiratory cofactor and liposoluble antioxidant. Studies have shown that plants derive approximately a quarter of 4-hydroxybenzoate, which serves as the direct ring precursor of ubiquinone, from the catabolism of kaempferol. Biochemical and genetic...

Cite
Berger A, Latimer S, Stutts LR, et al. Kaempferol as a precursor for ubiquinone (coenzyme Q) biosynthesis: An atypical node between specialized metabolism and primary metabolism. Curr Opin Plant Biol. 2022;66:102165doi: 10.1016/j.pbi.2021.102165.
Berger, A., Latimer, S., Stutts, L. R., Soubeyrand, E., Block, A. K., & Basset, G. J. (2022). Kaempferol as a precursor for ubiquinone (coenzyme Q) biosynthesis: An atypical node between specialized metabolism and primary metabolism. Current opinion in plant biology, 66102165. https://doi.org/10.1016/j.pbi.2021.102165
Berger, Antoine, et al. "Kaempferol as a precursor for ubiquinone (coenzyme Q) biosynthesis: An atypical node between specialized metabolism and primary metabolism." Current opinion in plant biology vol. 66 (2022): 102165. doi: https://doi.org/10.1016/j.pbi.2021.102165
Berger A, Latimer S, Stutts LR, Soubeyrand E, Block AK, Basset GJ. Kaempferol as a precursor for ubiquinone (coenzyme Q) biosynthesis: An atypical node between specialized metabolism and primary metabolism. Curr Opin Plant Biol. 2022 Jan 10;66:102165. doi: 10.1016/j.pbi.2021.102165. Epub 2022 Jan 10. PMID: 35026487.
Copy Download .nbib Format: NLM
Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma.

Frontiers in oncology

Swayden M, Soubeyran P, Iovanna J.
PMID: 32038993
Front Oncol. 2020 Jan 22;9:1443. doi: 10.3389/fonc.2019.01443. eCollection 2019.

To date, PDAC remains the cancer having the worst prognosis with mortality rates constantly on the rise. Efficient cures are still absent, despite all attempts to understand the aggressive physiopathology underlying this disease. A major stumbling block is the...

Cite
Swayden M, Soubeyran P, Iovanna J. Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. Front Oncol. 2020;9:1443doi: 10.3389/fonc.2019.01443.
Swayden, M., Soubeyran, P., & Iovanna, J. (2019). Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. Frontiers in oncology, 91443. https://doi.org/10.3389/fonc.2019.01443
Swayden, Mirna, et al. "Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma." Frontiers in oncology vol. 9 (2019): 1443. doi: https://doi.org/10.3389/fonc.2019.01443
Swayden M, Soubeyran P, Iovanna J. Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. Front Oncol. 2020 Jan 22;9:1443. doi: 10.3389/fonc.2019.01443. eCollection 2019. PMID: 32038993; PMCID: PMC6987422.
Copy Download .nbib Format: NLM
Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France.

Biology

Roques L, Klein EK, Papaïx J, Sar A, Soubeyrand S.
PMID: 32397286
Biology (Basel). 2020 May 08;9(5). doi: 10.3390/biology9050097.

The number of screening tests carried out in France and the methodology used to target the patients tested do not allow for a direct computation of the actual number of cases and the infection fatality ratio (IFR). The main...

Cite
Roques L, Klein EK, Papaïx J, et al. Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France. Biology (Basel). 2020;9(5)doi: 10.3390/biology9050097.
Roques, L., Klein, E. K., Papaïx, J., Sar, A., & Soubeyrand, S. (2020). Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France. Biology, 9(5), . https://doi.org/10.3390/biology9050097
Roques, Lionel, et al. "Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France." Biology vol. 9,5 (2020). doi: https://doi.org/10.3390/biology9050097
Roques L, Klein EK, Papaïx J, Sar A, Soubeyrand S. Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France. Biology (Basel). 2020 May 08;9(5). doi: 10.3390/biology9050097. PMID: 32397286; PMCID: PMC7284549.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 87 entries